[1]
|
Wang, F.H., Zhang, X.T., Li, Y.F., et al. (2021) The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer, 2021. Cancer Communications (London, England), 41, 747-795.
|
[2]
|
王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 中国病毒病杂志, 2020, 10(1): 1-25.
|
[3]
|
Pattullo, V. (2016) Prevention of Hepatitis B Reactivation in the Setting of Immunosuppression. The Korean Journal of Hepatology, 22, 219-237.
|
[4]
|
陈洁, 王健民, 杨建民, 等. 不同细胞类型非霍奇金淋巴瘤患者合并HBV感染的临床评价[J]. 临床血液学杂志, 2014, 27(9): 760-765.
|
[5]
|
Dalia, S., Chavez, J., Castillo, J.J., et al. (2013) Hepatitis B Infection Increases the Risk of Non-Hodgkin Lymphoma: A Meta-Analysis of Observational Studies. Leukemia Research, 37, 1107-1115.
https://doi.org/10.1016/j.leukres.2013.06.007
|
[6]
|
Bilgehan, A., Muzaffer, D.A., Mahmut, G., et al. (2018) Immunosuppressive Therapy and the Risk of Hepatitis B Reactivation: Consensus Report. The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology, 29, 259-269.
|
[7]
|
Kusumoto, S., Arcaini, L., Hong, X.N., et al. (2019) Risk of HBV Reactivation in Patients with B-Cell Lymphomas Receiving Obinutuzumab or Rituximab Immunochemotherapy. Blood, 133, 137-146.
https://doi.org/10.1182/blood-2018-04-848044
|
[8]
|
Di Bisceglie Adrian, M., Lok, A.S., Martin, P., et al. (2015) Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation with Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg? Hepatology (Baltimore, Md.), 61, 703-711. https://doi.org/10.1002/hep.27609
|
[9]
|
Cho, Y., et al. (2016) High Titers of Anti-HBs Prevent Rituximab-Related Viral Reactivation in Resolved Hepatitis B Patient with Non-Hodgkin’s Lymphoma. Journal of Medical Virology, 88, 1010-1017.
https://doi.org/10.1002/jmv.24423
|
[10]
|
Seto, W.-K., Chan, T.S.Y., Hwang, Y.-Y., et al. (2014) Hepatitis B Reactivation in Patients with Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32, 3736-3743.
https://doi.org/10.1200/JCO.2014.56.7081
|
[11]
|
王成伟, 咸建春. 隐匿性乙型肝炎病毒感染的研究进展[J]. 河北医学, 2021, 27(2): 348-352.
|
[12]
|
Cao, X., Wang, Y.F., Li, P.Y., et al. (2021) HBV Reactivation during the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Frontiers in Oncology, 11, Article ID: 685706. https://doi.org/10.3389/fonc.2021.685706
|
[13]
|
Hara, T., Oka, K., Iwai, N., et al. (2021) Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma: Case Reports. Internal Medicine, 60, 417-421. https://doi.org/10.2169/internalmedicine.5678-20
|
[14]
|
陈彦帆, 韦燕, 龚建忠, 等. 恶性肿瘤化疗与乙肝病毒再激活及相关高危因素的临床分析[J]. 实用癌症杂志, 2012, 27(1): 45-47+57.
|
[15]
|
董琳. 乳腺癌化疗相关HBV再激活的研究进展[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2017.
|
[16]
|
杨少江, 徐理华, 曾萍, 等. R-CHOP方案对淋巴瘤患者免疫球蛋白及T细胞亚群的影响[J]. 临床血液学杂志, 2014, 27(7): 577-580.
|
[17]
|
张佳莹, 梁连春, 冯茹. 美罗华致乙型肝炎康复者乙型肝炎再活动1例及文献回顾[J]. 肝脏, 2018, 23(7): 652-653.
|
[18]
|
He, H., Li, X.Y., Zhu, J., et al. (2014) Entecavirvs Lamivudine for Prevention of Hepatitis B Virus Reactivation among Patients with Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy: A Randomized Clinical Trial. JAMA, 312, 2521-2530. https://doi.org/10.1001/jama.2014.15704
|
[19]
|
Chen, K.-L., Chen, J., Rao, H.-L., et al. (2015) Hepatitis B Virus Reactivation and Hepatitis in Diffuse Large B-Cell Lymphoma Patients with Resolved Hepatitis B Receiving Rituximab-Containing Chemotherapy: Risk Factors and Survival. Chinese Journal of Cancer, 34, 18. https://doi.org/10.1186/s40880-015-0015-9
|
[20]
|
马军, 秦叔逵, 缪晓辉, 等. 淋巴瘤免疫化疗乙型肝炎病毒再激活预防和治疗中国专家共识[J]. 中国实用内科杂志, 2014, 34(1): 32-39.
|
[21]
|
张梦阳, 张硕, 周宝桐, 等. 乙型肝炎病毒再激活及其预防性治疗[J]. 中华实验和临床感染病杂志(电子版), 2017, 11(1): 4-9.
|
[22]
|
黎振威, 盛慧萍, 杨岩, 等. 美罗华治疗胃MALT淋巴瘤致乙型肝炎再活动并发急性肝衰竭1例[J]. 宁夏医科大学学报, 2018, 40(12): 1463-1464.
|
[23]
|
Tang, S.H. (2015) American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation during Immunosuppressive Drug Therapy. Chinese Journal of Clinical Hepatology, 31, 215-219.
|